Loi, Sherene http://orcid.org/0000-0001-6137-9171
Salgado, Roberto http://orcid.org/0000-0002-1110-3801
Adams, Sylvia
Pruneri, Giancarlo
Francis, Prudence A. http://orcid.org/0000-0002-7207-9286
Lacroix-Triki, Magali http://orcid.org/0000-0002-6641-8536
Joensuu, Heikki http://orcid.org/0000-0003-0281-2507
Dieci, Maria Vittoria
Badve, Sunil http://orcid.org/0000-0001-8861-9980
Demaria, Sandra http://orcid.org/0000-0003-4426-0499
Gray, Robert http://orcid.org/0000-0002-5724-4917
Munzone, Elisabetta http://orcid.org/0000-0003-3371-3878
Drubay, Damien
Lemonnier, Jerome
Sotiriou, Christos http://orcid.org/0000-0002-5745-9977
Kellokumpu-Lehtinen, Pirkko Liisa http://orcid.org/0000-0002-5557-0911
Vingiani, Andrea
Gray, Kathryn
André, Fabrice http://orcid.org/0000-0001-5795-8357
Denkert, Carsten http://orcid.org/0000-0002-2249-0982
Piccart, Martine
Roblin, Elvire
Michiels, Stefan
Article History
Received: 28 May 2021
Accepted: 3 November 2021
First Online: 11 January 2022
Competing interests
: S.L. receives research funding to her institution from Novartis, Bristol Meyers Squibb, Merck, Puma Biotechnology, Eli Lilly, Nektar Therapeutics Astra Zeneca, Roche-Genentech and Seattle Genetics. S.L. has acted as consultant (not compensated) to Seattle Genetics, Novartis, Bristol Meyers Squibb, Merck, AstraZeneca and Roche-Genentech. S.L. has acted as consultant (paid to her institution) to Aduro Biotech, Novartis, GlaxoSmithKline, Roche-Genentech, Astra Zeneca, Silverback Therapeutics, G1 Therapeutics, Daiichi Sankyo, PUMA Biotechnologies, Seattle Genetics and Bristol Meyers Squibb. RS reports non-financial support from Merck and Bristol Myers Squibb; research support from Merck, Puma Biotechnology, and Roche; and personal fees from Roche for an advisory board related to a trial-research project. S.D. has received honorarium as a member of the scientific advisory board of Lytix Biopharma, and ad hoc consulting for Ono Pharmaceuticals. M.P. is a Scientific Board Member of Oncolytics. M.P. has acted as a consultant (compensated) to AstraZeneca, Camel-IDS/Precirix, Gilead, Immunomedics, Lilly, Menarini, MSD, Novartis, Odonate, Pfizer, Roche-Genentech, Seattle Genetics, Immutep, Seagen, NBE Therapeutics, Frame Therapeutics. M.P. receives research funding to her institution from AstraZeneca, Immunomedics, Lilly, Menarini, MSD, Novartis, Pfizer, Radius, Roche-Genentech, Servier, Synthon. E.M. has acted as a consultant (compensated) to Pierre Fabre, Genomic Health and Eisai. E.M. has received funding for travel expenses and/or accommodation from Celgene, Roche, Eisai, Mylan and Pfizer. C.D. reports stock and other ownership interests from Sividon Diagnostics (unitl 2016), honoraria from Novartis and Roche. C.D. has acted as a consultant (compensated) to MSD Oncology, Daiichi Sankyo, Molecular Health, Astra Zeneca, merck. C.D. receives research funding (to institution) from Myriad Genetics and Roche. C.D. reports patents, royalties and/or other intellectual property from VMScope digital pathology software, patent applications WO2015114146A1 and WO2010076322A1(therapy response) and WO2020109570A1 (cancer immunotherapy). C.D. has received funding for travel expenses and/or accommodation from Roche. H.J. is the Chair of the Scientific Advisory Board at Orion Pharma and at Neutron Therapeutics Ltd. S.M. reports fees outside the submitted work from statistical advice (IDDI, Janssen Cilag, Amaris, Roche) and from data and safety monitoring membership of clinical trials (Hexal, Steba, IQVIA, Sensorion, Biophytis, Servier, Yuhan. F.A. received research funding and served as speaker / advisor (compensated to the hospital) for Roche, AstraZeneca, Daiichi Sankyo, Pfizer, Novartis, Lilly. S.A. has uncompensated consulting or advisory roles with Bristol Meyers Squibb, Genentech, and Merck as well as research funding to her institution from Amgen, Bristol Meyers Squibb, Celgene, Genentech, Merck and Novartis. M.V.D. reports personal fees for consultancy/advisory from Eli Lilly, Pfizer, Novartis, Genomic Health. MLT reports honorarium/expertise from Roche, Roche Diagnostics, MSD, AstraZeneca, Daiichi Sankyo. P.L.K.L. has received honorarium as member of advisory board of Bristol Myers Squibb and has received compensation for traveling from Sanofi. PAF reports honoraria from AstraZeneca and Novartis and travel support from Pfizer and Ipsen. The remaining authors declare competing interests.